<DOC>
	<DOCNO>NCT01131247</DOCNO>
	<brief_summary>Investigational Drugs : Ofatumumab ( Azerra ) + bendamustine ( Trenda ) Route Administration : Intravenous ( IV ) Hypothesis : This study design assess toxicity overall response rate . Ofatumumab fully human monoclonal antibody ( A type protein make laboratory bind substance body , include tumor cell ) show promising activity treatment CLL single agent . It think combine Bendamustine , FDA approve treatment CLL , effect CLL great Ofatumumab give alone . Ofatumumab FDA approve treatment relapsed/refractory CLL . Participation : Approximately 37 relapsed/refractory CLL subject participate study two year . Treatment Plan : A maximum 6 cycle treatment allow . During day 1 cycle 1 ofatumumab IV 300mg administer . On day 1 cycle ofatumumab treatment follow bendamustine IV 90mg/m2 . On day 2 cycle , bendamustine IV 90mg/m2 administer . On day 3 cycle , neulasta SQ 6mg give . On day 8 cycle 1 patient receive ofatumumab IV 1000mg . During cycle 2 6 ofatumumab 1000mg give day 1 . Follow-up : Patients follow monthly six month , every three month five year annually thereafter .</brief_summary>
	<brief_title>PH2 Trial Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia ( CLL ) With Combination Bendamustine &amp; Ofatumumab</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Must &gt; /= 18 year old able provide consent Must diagnosis CLL define NCI criterion Must require chemotherapy Must previously treat minimum one course prior chemo treatment Serum creatinine &lt; 1.8 mg/dl Bilirubin must &lt; /= 2 mg/d , unless secondary tumor Must adequate liver function ( define &lt; 2x ULN , unless relate CLL ) AST/ALT &lt; 2x ULN Performance status 02 Women child bear age must willing use accepted/effective method birth control . Not received prior treatment cytotoxic chemotherapy immunotherapy . Not autoimmune hemolytic anemia autoimmune thrombocytopenia Not history corticosteroid treatment CLL Not CNS disease Not clinically significant infection Patients second malignancy , basal cell carcinoma skin situ carcinoma cervix eligible . Not positive serology Hepatitis B Hepatitis C Not know HIV positive Not New York Classification III IV hear disease Other protocol specific criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>CLL</keyword>
	<keyword>bendamustine</keyword>
	<keyword>ofatumumab</keyword>
	<keyword>blood cancer</keyword>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
	<keyword>lymphocyte</keyword>
	<keyword>refractory</keyword>
	<keyword>Advanced</keyword>
	<keyword>relapse</keyword>
	<keyword>hematologic</keyword>
	<keyword>hematology</keyword>
	<keyword>antibody</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
	<keyword>nevada cancer institute</keyword>
	<keyword>cephalon</keyword>
	<keyword>Glaxosmithkline</keyword>
</DOC>